Lower Rates of In-Stent Thrombosis with the New Generation DES

Original title: New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry. Reference: Vignali L et al. Cath Cardiovasc Interv. 2014; Epub ahead of print.

Compared to the first generation of drug eluting stents (DES), the new generation has a lower long term risk of in-stent thrombosis and acute myocardial infarction (AMI).

This study analyzed data from 2775 patients receiving first generation DES and 2557 receiving new generation DES included in the REAL registry (multicenter registry in the north of Italy) between 2007 and 2011.

At 3 years, new generation DES were associated to lower AMI and definite thrombosis rates comparted to the first DES, though the combined events rate (death, infarction and revascularization) were no different between the groups. 

After propensity score matching, 3 year death rates turned out similar (new generation 7% vs. first generation 8.7%, HR 0.85, IC 0.68 to 1.06) as well as infarction rate (new generation 5% vs. first generation 7.4%, HR 0.65, IC 0.5 to 0.82) and revascularization (10.9% vs. 13.5% respectively, HR 0.99, IC 0.84 to 1.16). The only significant difference was seen in definite thrombosis rates (new generation 0.5% vs. first generation 1.1%, HR 0.35, IC 0.17 to 0.72).

Conclusion

This multicenter registry included data from real life patients confirming that new generation DES compared to first generation DES are associated with similar efficacy but a greater long term safety, due to the lower in-stent thrombosis and AMI rates.

Editorial Comment

Several randomized studies and meta-analysis had shown that newer DES has a better safety profile; however, the present study is one of the largest registries, with the longest follow up period, which confirmed these outcomes in the daily practice.

SOLACI

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....